Executive Overview The landscape of haematological oncology has been fundamentally reshaped by groundbreaking immunotherapies, specifically chimeric antigen receptor (CAR) T-cell...
Executive Overview Chimeric antigen receptor T-cell (CAR T) therapy stands as one of the most remarkable breakthroughs in modern oncology....
In recent decades, the global medical community has grown accustomed to a familiar narrative regarding pediatric cholelithiasis—the presence of gallstones...
Executive Overview Cutaneous T-cell lymphomas (CTCLs) represent a complex, highly heterogeneous group of lymphoproliferative neoplasms characterized by the clonal proliferation...
Executive Overview Acute lymphoblastic leukemia (ALL) stands as the most prevalent pediatric malignancy globally, yet a profound disparity persists in...
Executive Overview For decades, the standard management of high-risk acute promyelocytic leukemia (APL)—defined by a presenting white blood cell (WBC)...
Published: June 10, 2026 | Frontiers in Hematology Executive Overview For more than half a century, cytotoxic chemotherapy has offered...
Executive Overview For decades, disease relapse following allogeneic hematopoietic cell transplantation (allo-HCT) has represented one of the most formidable and...
A landmark global study has cast a long-overdue spotlight on the profound psychological, emotional, and social strain shouldered by informal...
In the intricate landscape of hematologic oncology, thrombotic complications are a recognized, albeit dreaded, hazard. Usually emerging in the crucible...
Acute myeloid leukemia (AML) has long stood as one of the most aggressive and formidable blood cancers known to modern...
Executive Overview Sickle cell disease (SCD) remains one of the world’s most pervasive and challenging inherited blood disorders, characterized by...
